Addus HomeCare matched Wall Street revenue expectations for its second quarter of 2026, while non-GAAP earnings per share and operating margins came in slightly ahead and held steady year on year. The stock has returned 11.05% over the past 30 days and 20.85% over 90 days, though the one-year total shareholder return stands at just 0.19%. A widely followed narrative pegs the fair value at $132.69 per share, implying the stock is undervalued at its recent price of $116.79. That valuation gap is supported by expected state-level reimbursement rate increases in Illinois and Texas, which are projected to add over $35 million in annualized revenue at stable margins of 20% or more. Key risks include potential Medicare reimbursement cuts and ongoing workforce pressures that could squeeze margins.
Addus HomeCare CorporationQ2 results matched revenue expectations with EPS and margins slightly ahead, and fair value estimate implies undervaluation.